Qin-Fu Feng

List of Publications by Citations

54 papers	350 citations	11 h-index	16 g-index
59 ext. papers	568 ext. citations	4 avg, IF	2.91 L-index

#	Paper	IF	Citations
54	Risk factors for brain metastases in locally advanced non-small cell lung cancer with definitive chest radiation. *International Journal of Radiation Oncology Biology Physics*, **2014**, 89, 330-7	4	36
53	Postoperative radiotherapy for completely resected Masaoka stage III thymoma: a retrospective study of 65 cases from a single institution. *Radiation Oncology*, **2013**, 8, 199	4.2	23
52	Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial. *JAMA Oncology*, **2021**, 7, 1178-1185	13.4	23
51	Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy. *Oncologist*, **2016**, 21, 1530-1537	5.7	22
50	A Proposal for Combination of Lymph Node Ratio and Anatomic Location of Involved Lymph Nodes for Nodal Classification in Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2016**, 11, 1565-73	8.9	20
49	Patterns and predictors of recurrence after radical resection of thymoma. *Radiotherapy and Oncology*, **2015**, 115, 30-4	5.3	16
48	A Single-Center Analysis of the Treatment and Prognosis of Patients With Thymic Carcinoma. *Annals of Thoracic Surgery*, **2017**, 104, 1718-1724	2.7	15
47	A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer. *Radiation Oncology*, **2019**, 14, 48	4.2	15
46	Nomogram to Predict Overall Survival for Thoracic Esophageal Squamous Cell Carcinoma Patients After Radical Esophagectomy. *Annals of Surgical Oncology*, **2019**, 26, 2890-2898	3.1	14
45	Postoperative Radiotherapy in Pathological T2-3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study. *Oncologist*, **2020**, 25, e701-e708	5.7	11
44	Nomogram and recursive partitioning analysis to predict overall survival in patients with stage IIB-III thoracic esophageal squamous cell carcinoma after esophagectomy. *Oncotarget*, **2016**, 7, 55211-55221	3.3	11
43	Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study. *Radiation Oncology*, **2019**, 14, 106	4.2	10
42	A propensity-score matching analysis comparing long-term survival of surgery alone and postoperative treatment for patients in node positive or stage III esophageal squamous cell carcinoma after R0 esophagectomy. *Radiotherapy and Oncology*, **2019**, 140, 159-166	5.3	10
41	Adjuvant radiotherapy for stage pN1M0 esophageal squamous cell carcinoma: Results from a Chinese two-center study. *Thoracic Cancer*, **2019**, 10, 1431-1440	3.2	9
40	Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma. *BMC Cancer*, **2020**, 20, 144	4.8	8
39	A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis. *Oncotarget*, **2017**, 8, 41102-41112	3.3	8
38	Histological subtypes of lung cancer in Chinese women from 2000 to 2012. *Thoracic Cancer*, **2014**, 5, 447-54	3.2	8

37	ExpertsUconsensus on intraoperative radiotherapy for pancreatic cancer. *Cancer Letters*, **2019**, 449, 1-7	9.9	7
36	Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer. *Radiation Oncology*, **2017**, 12, 195	4.2	7
35	Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial. *JAMA Network Open*, **2019**, 2, e1918070	10.4	7
34	The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases. *Journal of Cancer*, **2019**, 10, 1985-1990	4.5	6
33	Tobacco smoking and trends in histological subtypes of female lung cancer at the Cancer Hospital of the Chinese Academy of Medical Sciences over 13 years. *Thoracic Cancer*, **2019**, 10, 1717-1724	3.2	6
32	The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC). *Oncotarget*, **2017**, 8, 48922-48929	3.3	6
31	Ultrasound-guided intraoperative electron beam radiation therapy: A phantom study. *Physica Medica*, **2020**, 78, 1-7	2.7	6
30	A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma. *BMC Cancer*, **2020**, 20, 130	4.8	5
29	S-1-Based Chemoradiotherapy Followed by Consolidation Chemotherapy With S-1 in Elderly Patients With Esophageal Squamous Cell Carcinoma: A Multicenter Phase II Trial. *Frontiers in Oncology*, **2020**, 10, 1499	5.3	4
28	Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey. *Acta Oncol□gica*, **2021**, 60, 627-634	3.2	4
27	Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer. *Thoracic Cancer*, **2021**, 12, 814-823	3.2	4
26	CHST15 promotes the proliferation of TE-1 cells via multiple pathways in esophageal cancer. *Oncology Reports*, **2020**, 43, 75-86	3.5	3
25	A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non-small cell lung cancer. *Radiotherapy and Oncology*, **2021**, 156, 244-250	5.3	3
24	A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol. *BMC Cancer*, **2020**, 20, 901	4.8	2
23	Impact of thoracic radiation therapy after chemotherapy on survival in extensive-stage small cell lung cancer: A propensity score-matched analysis. *Thoracic Cancer*, **2019**, 10, 799-806	3.2	2
22	Debulking Surgery Plus Radiation: Treatment Choice for Unresectable Stage III Thymic Carcinoma. *Thoracic and Cardiovascular Surgeon*, **2020**, 68, 440-445	1.6	2
21	Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial. *BMC Cancer*, **2020**, 20, 278	4.8	2
20	A feasible study on using multiplexed sensitivity-encoding to reduce geometric distortion in diffusion-weighted echo planar imaging. *Magnetic Resonance Imaging*, **2018**, 54, 153-159	3.3	2

19	Development and validation of a prediction model using molecular marker for long-term survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy.. *Thoracic Cancer*, **2021**,	3.2	2
18	Primary intrathoracic liposarcoma: a clinical analysis of 31 cases. *Cancer Communications*, **2019**, 39, 15	9.4	1
17	Sclerosing thymoma: a case report and literature review.. *Translational Cancer Research*, **2020**, 9, 3034-3039	0.9	1
16	Myasthenia Gravis Is Not an Independent Prognostic Factor of Thymoma: Results of a Propensity Score Matching Trial of 470 Patients. *Frontiers in Oncology*, **2020**, 10, 583489	5.3	1
15	Sparing Organs at Risk with Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Locally Advanced Non-Small Cell Lung Cancer: An Automatic Treatment Planning Study. *Cancer Management and Research*, **2020**, 12, 9643-9653	3.6	1
14	Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: a prospective, multicenter clinical trial protocol. *BMC Cancer*, **2020**, 20, 877	4.8	1
13	Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis. *Thoracic Cancer*, **2021**, 12, 1831-1840	3.2	1
12	Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: A retrospective study of 133 cases. *Lung Cancer*, **2021**, 157, 116-123	5.9	1
11	Postoperative Adjuvant Therapy Versus Surgery Alone for Stage IIB-III Esophageal Squamous Cell Carcinoma: A Phase III Randomized Controlled Trial. *Oncologist*, **2021**, 26, e2151-e2160	5.7	1
10	Adenoid Cystic Carcinoma of Lobar Bronchial Origin: 20-Year Experience at a Single Institution.. *Annals of Surgical Oncology*, **2022**, 1	3.1	1
9	A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis.. *Frontiers in Oncology*, **2021**, 11, 781340	5.3	0
8	Long-term outcomes of intraoperative radiotherapy for early-stage breast cancer in China: a multicenter real-world study.. *Cancer Communications*, **2022**,	9.4	0
7	Recurrence risk stratification based on a competing-risks nomogram to identify patients with esophageal cancer who may benefit from postoperative radiotherapy.. *Therapeutic Advances in Medical Oncology*, **2021**, 13, 17588359211061948	5.4	0
6	Role of modern neoadjuvant chemoradiotherapy in locally advanced thymic epithelial neoplasms. *Tumori*, **2021**, 107, 407-415	1.7	0
5	Comparison of Two Major Staging Systems in Predicting Survival and Recommendation of Postoperative Radiotherapy Based on the 11th Japanese Classification for Esophageal Carcinoma After Curative Resection: A Propensity Score-Matched Analysis. *Annals of Surgical Oncology*, **2021**, 28, 7076-7086	3.1	0
4	Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer.. *Clinical Medicine Insights: Oncology*, **2022**, 16, 11795549221080347	1.8	0
3	Definitive Simultaneous Integrated Boost Versus Conventional-Fractionated Intensity Modulated Radiotherapy for Patients With Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis. *Frontiers in Oncology*, **2021**, 11, 618776	5.3	
2	ASO Author Reflections: Surgery With or Without Additional Radiotherapy as a Therapeutic Strategy in ACC of Lobar Bronchial Origin.. *Annals of Surgical Oncology*, **2022**, 1	3.1	

List of Publications

1	Chemoradiotherapy is an alternative choice for patients with primary mediastinal seminoma.. *Radiation Oncology*, **2022**, 17, 58	4.2